Please login to the form below

Not currently logged in
Email:
Password:

vintafolide

This page shows the latest vintafolide news and features for those working in and with pharma, biotech and healthcare.

Amgen's trebananib misses survival target in ovarian cancer

Amgen's trebananib misses survival target in ovarian cancer

Other candidates coming through the pipeline include Boehringer Ingelheim's triple angiokinase inhibitor nintedanib, Merck &Co's anti-folate drug vintafolide, AstraZeneca's PARP inhibitor olaparib and Array BioPharma/Novartis's

Latest news

  • Merck's vintafolide fails ovarian cancer trial Merck's vintafolide fails ovarian cancer trial

    PROCEED compared the combination of vintafolide and pegylated liposomal doxorubicin to a combination of doxorubicin and placebo. ... Merck licensed rights to vintafolide in 2012 in a deal valued at up to $1bn, including $120m upfront.

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Endocyte's vintafolide is a folate-targeted conjugate composed of a folate molecule plus a vinca alkaloid, which acts as a microtubule destabilising agent. ... Vintafolide targets and enters cancer cells via the folate vitamin receptor, which is

  • Merck's vintafolide shows its worth in ovarian cancer Merck's vintafolide shows its worth in ovarian cancer

    Phase II data shows improvement on current oncology treatments. Merck &Co's cancer drug candidate vintafolide has improved on standard treatment for women with ovarian cancer, according to newly-published phase ... Vintafolide is a small molecule drug

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics